Hyperhemolysis syndrome in sickle cell disease

References

• Friedman DF, Kim HC, Manno CS. Hyperhaemolysis associated with red cell transfusion in sickle cell disease. Transfusion33(Suppl.), 148 (1993).
   Google Scholar
• Petz LD, Calhoun L, Shulman I, Johnson C, Herron R. The sickle cell haemolytic transfusion reaction syndrome. Transfusion37, 382–392 (1997).
   PubMed Web of Science ®Google Scholar
• Cullis JO, Win N, Dudley JM, Kaye T. Post transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang.4, 355–357 (1995).
   Google Scholar
• Win N, Doughty H, Telfer P, Wild B, Pearson T. Hyperhaemolytic transfusion reaction in sickle cell disease. Transfusion41, 323–328 (2001).
   PubMed Web of Science ®Google Scholar
• Win N, Tullie Y, Needs M, Chen PE, Okpala I. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Haematology9, 433–436 (2004).
   Google Scholar
• Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion48, 1231–1238 (2008).
   PubMed Web of Science ®Google Scholar
• Talano JM, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed haemolytic transfusion reaction/hyperhaemolysis syndrome in children with sickle cell disease. Pediatrics111, 661–665 (2003).
   PubMedGoogle Scholar
• King KE, Shirey RS, Lankjewicz MW, Young-Ramsaran J, Ness P. Delayed haemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells. Transfusion37, 376–381 (1997).
   PubMed Web of Science ®Google Scholar
• Treleaven JG, Win N. Hyperhaemolysis syndrome in a patient with myelofibrosis. Haematology9, 147–149 (2004).
   Google Scholar
• Sirchia G, Moerelati F, Rebulla P. The sickle cell haemolytic transfusion reaction syndrome. Transfusion37, 1098–1099 (1997).
   PubMedGoogle Scholar
• Darabi K, Dzik S. Hyperhaemolysis syndrome in anaemia of chronic disease. Transfusion45, 1930–1933 (2005).
   PubMed Web of Science ®Google Scholar
• Win N. Blood transfusion therapy for haemoglobulinopathies. In: Practical Management of Haemoglobinopathies. Okpala I (Ed.). Blackwell Publishing, Oxford, UK 99–106 (2004).
   Google Scholar
• Petz LD, Garratty G. Bystander Immune Haemolysis Immune Haemolytic Anaemias (2nd Edition). Churchill Livingstone, PA, USA 358–364 (2004).
   Google Scholar
• Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion37, 357–361 (1997).
   PubMed Web of Science ®Google Scholar
• Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease potential role in the activation of vascular endothelium and vaso-occlusion. Blood96, 2451–2459 (2000).
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Tanaka Y, Fidler IJ et al. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J. Clin. Invest.75, 1965–1972 (1985).
   PubMed Web of Science ®Google Scholar
• Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood85, 268–274 (1995).
   PubMed Web of Science ®Google Scholar
• Ihanus E, Uotila LM. Toivanen A, Varis M, Gahmberg CG. Red cell ICAM-4 is a ligand for the monocyte/machrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood109, 802–810 (2007).
   PubMed Web of Science ®Google Scholar
• Takeuchi C, Ohto H, Miura S, Yasuda H, Ono S, Ogata T. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red cell-reactive HLA antibodies. Transfusion45, 1925–1929 (2005).
   PubMedGoogle Scholar
• Muro M, Palacios S, Moya-Quiles R, Candela M, Alvarez-Lopez R. Acute haemolytic transfusion reactions secondary to human leukocyte antigen alloimmunization. Int. J. Lab. Hematol.30(1), 84–86 (2008).
   PubMedGoogle Scholar
• Anderson D, Ali K, Blanchette V et al. Guidelines on the use of intravenous immune globulin for haematologyic conditions. Transfusion Med. Rev.21, S9–S56 (2007).
   PubMed Web of Science ®Google Scholar
• Provan D, Nokes TJC, Agrawal S, Winer J, Wood P. Clinical Guidelines for Immunoglobulin Use. Department of Health, London, UK (2008).
   Google Scholar
• Packer JT, Greendyke RM, Swisher SN. The inhibition of erythrophagocytosis in vitro by corticosteroids. Trans. Assoc. Am. Phys.73, 93–102 (1960).
   PubMedGoogle Scholar
• Krause J, Wu R, Sherer Y, Patanick M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious disease. Transfusion Med.12, 133–139 (2002).
   PubMed Web of Science ®Google Scholar
• Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venula vaso-occlusion in sickle cell mice by inhibiting erythrocytes and adherent leuckocytes. Blood15, 2397–2399 (2004).
   Google Scholar
• Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocyte–macrophage system as targets for immuno-modulation by intravenous immunoglobulin. Blood Rev.14, 14–30 (2000).
   PubMed Web of Science ®Google Scholar
• Mota MA, Sakashita AM, Hamerschlak N, Kutner JM, Castilho LM. Post-transfusion hyperhaemolysis after haemolytic transfusion reaction in a patient with severe anaemia: case report. Vox Sang.91(Suppl. 3), 125; (2006) (Abstract 233).
   Google Scholar
• Sherwood JB, Goldwasser E, Chilcote R et al. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood67, 46–49 (1986).
   PubMed Web of Science ®Google Scholar
• Trial J, Rice L. Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial–macrophage interface. Curr. Pharmaceut. Design10(2), 183–190 (2004).
   PubMedGoogle Scholar
• Hebbel RP, Miller VB. Phagocytosis of sickle erythrocyte: immunological and oxidative determinants of haemolytic anemia. Blood64, 733–741 (1984).
   PubMed Web of Science ®Google Scholar
• Mendoza E, Gutgsell N, Temple JD, Issitt P. Monocyte phagocyte activity in sickle cell disease. Acta Haematol.85, 199–201 (1991).
   PubMed Web of Science ®Google Scholar